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To the Editor: Colorectal cancer (CRC) is one of 
the most common malignant tumors worldwide 
(Gatta et al. 1998 [1], Repetto et al. 2003 [2]) with 
the disease incidence rising along with an advanced 
age (Wymenga et al. 2001 [3], Franceschi et al. 
2001 [4]). The overall mortality from CRC is 60%, 
which represents the second leading cause of 
cancer death in western societies. In Finland, the 
incidence of CRC is 25/100.000, and 20/100.000 
among males and females, respectively. Annually, 
1.150 new cases are detected among males and 
1.200 among women, representing 9.2% and 10% of 
all cancer cases, respectively (Finnish Cancer 
Registry, 2005). On the other hand, according to 
Benghazi Cancer Registry, 2003 [5] the colorectal 
cancer in eastern part of Libya is the most second 
frequent cancer after lung cancer in males and 
breast cancer in females. The average crude 
incidence rate is 6.4 (male) and 5.2 (female) cases 
per 100,000 inhabitants, representing 10.1% of male 
patients and 9.3% of female patients of all cancer 
cases.  
Unfortunately, there has not been a major 
improvement in patient survival despite the 
advances made in our understanding of disease and 
in chemotherapy practice (Walker and Quirke, 
2001[6]). Surgical cure of CRC is determined by 
stage of the tumor and its biological behaviour. Early 
CRCs can be cured with surgery alone. The decision 
to use adjuvant therapy to patients after curative 
surgical resection for stage II CRC (node-negative 
patients) is often difficult (Venook
   et al, 2004 [7]) 
and its routine use is not recommended (Graziano 
and Cascinu, 2003 [8]). In future, however, these 
decisions may be made more rationally as we learn 
how to incorporate the use of molecular markers and 
predictors in these patients. Recent guidelines 
advocate considering factors such as tumor 
differentiation, tumor perforation, number of lymph 
nodes examined, and T stage when assessing the 
likely benefit: risk ratio. Microsatellite instability and 
allelic imbalance seem to be strong predictors of 
good and poor prognosis, respectively, and in the 
near future, therapeutic decision-making models are 
likely to be further refined by the inclusion of such 
molecular markers [9]. The well-known and 
important prognostic factors in patients with CRC are 
histological tumor stage (Dukes-classification) 
including the depth of invasion and lymph node 
infiltration (Phillips et al 1984 [10], Wiggers et al, 
1988 [11], Rapponen et al, 1996 [12]). Molecular 
markers may help deciding adjuvant therapy for a 
subgroup of these patients. Because the 5-year 
survival in stage II patients is approximately 70% 
with surgery alone (Wang et al, 2003 [13]), 
adjuvant therapy is not widely recommended and 
still no agreement exists on the use of 
chemotherapy for these patients (Di Fabio et al, 
2004 [14]). However, it is well established that a 
sub-group of patients with stage II CRC are at 
high risk of recurrence and should be considered 
for adjuvant chemotherapy (Willett et al, 1999 
[15]). Some studies have suggested a definite 
survival benefit from chemotherapy in this sub-
group of node-negative patients (Venook
   et al, 
2004). To date, most of the randomized trials have 
demonstrated a relative reduction in tumor 
recurrence but have not shown any significant 
impact on survival in stage II disease, however. It 
seems likely that this failure to demonstrate a 
survival benefit from adjuvant chemotherapy in 
stage II disease is due to the fact that these trials 
do not have enough statistical power due to small 
patient series. Nevertheless, the absolute survival 
advantage is only about 2% and clinicians need to 
weigh this against the costs and toxicities of the 
treatment when managing these patients (Haydon 
A, 2003 [16]). In brief, the main long-term goal of 
building up a prognostic model (index) in stage II 
CRC is to accurately: 1) Predict patients who are 
at high risk for developing recurrent disease, 2) 
Identify the patients among stage II cases who 
should benefit from adjuvant chemotherapy, and   
finally 3) Predict the overall disease outcome. 
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